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Abstract. Signal transducer and activator of transcription 3
(STAT3) is aberrantly activated in human cancer including
lung cancer and has been implicated in transformation,
tumorigenicity, and metastasis. One putative downstream gene
regulated by STAT3 is MUC1 which also has important roles
in tumorigenesis. We determined if STAT3 regulates MUC1
in lung cancer cell lines and what function MUC1 plays in
lung cancer cell biology. We examined MUC1 expression in
non-small cell lung cancer (NSCLC) cell lines and found
high levels of MUC1 protein expression associated with
higher levels of tyrosine phosphorylated STAT3. STAT3
knockdown downregulated MUC1 expression whereas
constitutive STAT3 expression increased MUC1 expression at
mRNA and protein levels. MUC1 knockdown induced
cellular apoptosis concomitant with reduced Bcl-XL and
sensitized cells to cisplatin treatment. MUC1 knockdown
inhibited tumor growth and metastasis in an orthotopic mouse
model of lung cancer by activating apoptosis and inhibiting
cell proliferation in vivo. These results demonstrate that
constitutively activated STAT3 regulates expression of
MUC1, which mediates lung cancer cell survival and
metastasis in vitro and in vivo. MUC1 appears to be a
cooperating oncoprotein with multiple oncogenic tyrosine
kinase pathways and could be an effective target for the
treatment of lung cancer.
Introduction
Signal transducer and activator of transcription (STAT)
proteins are persistently activated in a wide variety of human

_________________________________________
Correspondence to: Dr Eric B. Haura, Thoracic Oncology and
Experimental Therapeutics Program, H. Lee Moffitt Cancer Center
and Research Institute, MRC3 East, Room 3056, 12902 Magnolia
Drive, Tampa, FL 33612-9497, USA
E-mail: eric.haura@moffitt.org

Key words: MUC1, signal transducer and activator of transcription 3,
small interfering RNA, apoptosis, metastasis, lung cancer

malignancies and can be required for survival of carcinoma
cells (1,2). STAT3 has been found to be a critical mediator of
the oncogenic effects in non-small cell lung cancer (NSCLC)
(2-4). It is activated by diverse receptor and non-receptor
tyrosine kinases and plays a crucial role in oncogenesis by
regulating genes important in cellular proliferation, survival,
angiogenesis, and invasion/metastasis (5). Critical downstream genes important for the oncogenic effect of STAT3
include cyclin D, Myc, Bcl-XL, Mcl-1 and VEGF. Other
downstream genes have been reported, but their significance
in promoting tumor growth remains unclear in lung cancer
(6).
One potential gene downstream of STAT3 important in
oncogenesis is MUC1. The promoter of the MUC1 gene
contains a STAT-responsive element, and STAT3 constitutively binds to promoters of MUC genes (7,8). Inhibition of
STAT3 expression reduced expression of MUC genes and
inhibited cellular motility in breast cancer cells (8). MUC1 is a
mucin-like glycoprotein shown to be mainly expressed on the
apical border of normal secretory epithelial cells (9). There is
convincing evidence that the aberrantly overexpressed MUC1
is associated with transformation, tumorigenicity, invasion,
and metastasis of carcinomas and thus could be an important
downstream target of STAT3 (10-14). MUC1 is synthesized
as a single polypeptide which is cleaved in the endoplasmic
reticulum into N-terminal (MUC1-N, >200 kDa) and Cterminal (MUC1-C, ~25 kDa) subunits. Previous studies
have demonstrated that the MUC1 cytoplasmic tail interacts
with a variety of signals involved in cell growth, adhesion,
and survival including multiple HER family members, c-Src,
protein kinase C, and Grb2/SOS (10,15-20). MUC1 activates
the anti-apoptotic phosphoinositide 3-kinase (PI3K)/Akt and
Bcl-XL pathways. MUC1-C also localizes to the mitochondria,
attenuating the apoptotic response to DNA damage and
conferring resistance to genotoxic anticancer agents (21-23).
In addition to these laboratory-based studies, clinical studies
have reported that MUC1 expression in lung cancer is
associated with nodal metastasis and advanced stage of
disease (24).
Based on these studies, we hypothesized that STAT3
might be one of the important regulators of MUC1
transcription and contributes to MUC1 overexpression in
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these cells. In the present study, we demonstrated that MUC1
is aberrantly overexpressed in a wide variety of NSCLC cell
lines, is associated with higher levels of activated STAT3,
and is regulated by STAT3 function. The major function of
MUC1 is to drive cell survival and invasion/migration of
NSCLC cells both in vitro and in vivo. We validated MUC1
as an important regulator of lung cancer cell survival.
Materials and methods
Antibodies. MUC1 Ab-5, a hamster monoclonal antibody
which recognizes the MUC1-C of both human and mouse
MUC1, and anti-Ki-67 (clone SP6) were purchased from Lab
Vision (Fremont, CA) (10,25). Anti-total STAT3, anti-Bcl-2,
anti-Bcl-XL, and goat anti-mouse IgG horseradish
peroxidase (HRP)-conjugated secondary antibody were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
Anti-phosphorylated STAT3 (Tyr705), anti-total Src, antiphosphorylated Src (Tyr416), anti-total focal adhesion kinase
(FAK), anti-total Akt, anti-phosphorylated Akt (Ser473), and
anti-cleaved PARP (C-PARP) were purchased from Cell
Signaling Technology (Danvers, MA). Anti-phosphorylated
FAK (Tyr397 and Tyr861) was purchased from BioSource
(Camarillo, CA). Anti-cytokeratin (clones AE1/AE3) was
purchased from Dako (Carpinteria, CA). Alexa Fluor 488
F(ab')2 fragment of goat anti-mouse IgG and Alexa Fluor 633
F(ab')2 fragment of goat anti-rabbit IgG were purchased from
Invitrogen (Eugene, OR). Texas red dye-conjugated
AffiniPure goat anti-Armenian hamster IgG was purchased
from Jackson ImmunoResearch Laboratories (West Grove,
PA). Anti-ß-actin and donkey anti-rabbit IgG HRPconjugated secondary antibody were purchased from Sigma
(St. Louis, MO) and Amersham Biosciences (Piscataway,
NJ), respectively.
Cell lines and culture. Human NSCLC cells were maintained
in RMPI-1640 culture medium supplemented with 10% heatinactivated (56˚C, 30 min) newborn calf serum (Invitrogen,
Grand Island, NY). HCC827 and H4006 cells were provided
by Dr Jonathan M. Kurie (University of Texas M.D. Anderson
Cancer Center, Houston, TX). H226, H820, and H2279 cells
were provided by Dr John D. Minna (University of Texas
Southwestern Medical Center, Dallas, TX). PC-9 cells were
provided by Dr Matthew Lazzara (Massachusetts Institute of
Technology, Boston, MA). The other cell lines were purchased
from American Type Culture Collection (Manassas, VA).
Monolayer cultures were incubated at 37˚C in a 95%
humidified atmosphere containing 5% CO2. For generation of
the stable luciferase H358 cell line (Luc-H358), H358 cells
were transfected with pCMVneo-luciferase plasmid at ~6070% confluent density using Fugene 6 transfection reagent
(Roche, Indianapolis, IN) according to the manufacturer's
instructions. Luc-H358 cells were selected with 800 μg/ml
G418 sulfate (Invitrogen), beginning 48 h post-transfection,
and neomycin-resistant clones were isolated with cloning
cylinders by trypsin-EDTA. Stable clones with high-intensity
luciferin bioluminescence used for in vivo study were
determined with the Xenogen 200 Imaging System 30 min
after addition of the 1X D-luciferin solution (Xenogen,
Alameda, CA).

Real-time RT-PCR analysis. Cells were harvested at 80%
confluent density, and RNA was isolated using Trizol reagent
(Invitrogen). cDNA was synthesized from 500 ng of RNA
using Protoscript MLV reverse transcriptase (New England
Biolabs, Beverly, MA). Expression of GAPDH (internal
control) and MUC1 mRNAs was assessed using Taqman
FAM-labeled probes (Applied Biosystems, Foster City, CA)
according to the manufacturer's instructions. A pooled cDNA
sample was used in construction of standard curves and
calculation of relative expression.
Transfections. A549 cells were transiently transfected with
plasmids of pIRES-puro2-vector or pIRES-puro2-MUC1 at
~60-70% confluent density using Fugene 6 transfection
reagent as described above. The MUC1 plasmid (17) was
kindly provided by Dr Donald Kufe (Dana-Farber Cancer
Center, Boston, MA). At 48 h after transfection, cells were
harvested and subjected to protein analysis. For adenoviral
infections, A549 cells were infected with either a control
adenovirus expressing green fluorescent protein (Ad-GFP) or
a STAT3 mutant (Ad-STAT3C) as previously described (6).
After 13 h of infection, cells were costimulated with IL-6
(20 ng/ml) for an additional 5 h before being collected for
RNA analysis. STAT3 antisense and mismatch oligonucleotides were kindly provided by ISIS Pharmaceuticals
and have been previously described (2).
Small interfering RNA treatment. Cells were reverse
transfected with 20 nM small interfering RNA (siRNA) using
lipofectamine RNAiMAX transfection reagent (Invitrogen)
according to the manufacturer's instructions. The MUC1
siRNA (On-Target plus SMART pool) and the nonspecific
control siRNA were supplied by Dharmacon. After a 72-h
incubation or at indicated time points, cells were harvested or
trypsinized and replated for subsequent experiments.
Cell proliferation assay. Cells were plated in 96-well plates,
and siRNA transfection was performed for 120 h as described
above. Cellular proliferation was measured by [3-(4,5)dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide
(MTT) analysis (26). Briefly, after cells were washed with
PBS, they were incubated in MTT solution for 4 h and then
supplemented with 100 μl of dissolving solution (10% SDS
in 0.01 M HCl). The absorbance (optical density units) was
measured with a microplate spectrophotometer (Bio-Rad
Laboratories, Hercules, CA) with Microplate Manager 5.1
software at wavelengths of 590 and 660 nm. Each assay was
performed in quadruplicate. Cell viability of siRNAtransfected cells after a 48-h exposure to the chemotherapeutic agent cisplatin (CDDP) was also evaluated by
MTT assay.
Flow cytometry analysis. After a 72-h treatment with siRNAs,
cells were subjected to flow cytometry analyses of apoptosis
and cell cycle alterations. Apoptosis was assayed using
Pharmingen (San Diego, CA) PE-conjugated monoclonal
active caspase-3 antibody apoptosis kit without modification.
We determined the percentage of cells in G1, S, and G2/M by
propidium iodide staining as described previously (2). A total
of 10,000 cells per experimental condition was used for
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processing and analysis of fluorescence (FACScan; BectonDickinson, Franklin Lakes, NJ) using CellQuest software.
Colony formation assay. After a 72-h treatment with siRNAs,
cells were collected and mixed (1000/ml) with RPMI-1640
culture medium containing 10% fetal bovine serum (FBS;
Invitrogen) and added to 12-well plates (1 ml/well). After
cells were plated for 14 days, we counted the number of
colonies per well using a Nikon inverted microscope; each
assay was performed in triplicate.
Migration and invasion assays. To measure cell migration,
we used an 8-μm pore size Boyden chamber (Corning, NY).
Equal amounts of control siRNA- and MUC1 siRNAtransfected cells (100,000) in medium plus 0.1% bovine
serum albumin were plated on the top chamber, whereas
medium with 10% FBS plus 0.1% bovine serum albumin was
added to the lower chamber; chambers were plated in duplicate
and placed back into the incubator. For the cell invasion assay,
we used invasion chambers, which are identical to migration
chambers but precoated with 10 μg of growth factor-reduced
Matrigel (BD Biosciences, Bedford, MA), as described
previously (27). After ~22-24 h, cells remaining on the upper
surface of the chamber were removed with wet cotton swabs.
Cells on the lower surface of the inserts were fixed and stained
with the Hema3 stain set (Fisher Scientific, Middletown,
VA). Five fields of migrated or invaded cells were counted
under a microscope and averaged.
Western blot analysis. Cells were washed twice with cold
PBS and lysed with buffer A [10 mM Tris-HCl (pH 7.4),
1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS,
150 mM NaCl, 1 mM EDTA, 1 mM dithiothreitol, 0.5 mM
phenylmethylsulfonyl fluoride, 10 μg/ml leupeptin, and 5 μg/
ml aprotinin] as described previously (26). After incubation
for 30 min on ice, the suspensions were centrifuged (15,000 x g
for 30 min). The supernatants were removed and stored at
-80˚C until gel electrophoresis analyses. The protein concentration was determined by the Bio-Rad DC protein estimation
assay according to the manufacturer's instructions. For
Western blot analysis, ~60-100 μg of whole cell proteins
were separated using 10 or 12% SDS-PAGE and transferred
to nitrocellulose membranes. After membranes were blocked
with 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.1%
Tween-20 containing 5% nonfat dry milk at room temperature
for 60 min, the membranes were incubated with indicated
antibodies at 4˚C overnight and then with the HRP-conjugated
secondary anti-rabbit or anti-mouse antibodies at room
temperature for 60 min. Each protein was detected using the
Enhanced Chemiluminescence (Amersham Biosciences)
system. ß-actin was used as an internal control.
Orthotopic lung tumor model. Female athymic CD-1 nude
mice, 8 weeks old, purchased from Charles River Laboratories,
were anesthetized in an acrylic chamber using 2.5% isoflurane-air mixture and placed in the right lateral decubitus
position. Cells were transfected for 72 h, and then equal
amounts of viable control siRNA- and MUC1 siRNAtransfected Luc-H358 cells (1x106 viable cells determined by
trypan blue exclusion) in 50 μl of PBS containing 50 μg of
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growth factor-reduced Matrigel were injected into the left
lateral thorax of the mice at the lateral dorsal axillary line as
described previously (28). The mice (10 per group) were
housed and maintained in specific pathogen-free conditions.
The study was approved by and conducted in accordance
with the standards established by our Institutional Animal
Care and Use Committee. Ten days after injection, three mice
per group were randomized to be sacrificed, after which lung
tissue specimens were collected and formalin fixed for hematoxylin and eosin (H&E) staining and immunohistochemical
analyses. The remaining mice (7 per group) were euthanized
and autopsied when the first mouse became moribund, and
the relative tumor weight (total tumor-bearing lung weight),
pleural effusion, and mediastinal metastasis were evaluated.
Orthotopic tumor growth was also evaluated before sacrifice
by an in vivo bioluminescence assay using Xenogen Imaging
System 200, for which luciferin (150 mg/kg body weight)
was injected intraperitoneally 30 min before imaging.
Histology and immunohistochemistry. Formalin-fixed,
paraffin-embedded sections (5 μm) were stained with
hematoxylin and eosin (H&E). Immunofluorescence combined
with quantitative analysis was used to assess in situ expression
of MUC1 and Ki-67 as described previously (19,25). Antigens
were retrieved by incubating the tissue in a microwave oven.
Optimal concentrations of antibodies were used to detect
target molecules, which were ultimately visualized with the
use of fluorochrome-labeled secondary antibodies. DNA fragmentation (apoptosis) was detected with the ApopTag red in
situ apoptosis detection kit (Chemicon, Temecula, CA)
according to the manufacturer's instructions. We used a fully
automated, upright Carl Zeiss Axio-Imager Z.1 microscope
with a 20X/0.5 numerical aperture objective, and DAPI, FITC,
Texas red, and Cy5 filter cubes for immunofluorescence image
analysis. Images were produced using an AxioCam MRm
CCD camera and Axiovision version 4.6 software suite (Carl
Zeiss). Total intensities of the immunofluorescence from
absorbance of MUC1- and Ki-67-positive cells or the
percentage of cells positive for ApopTag in 10 random fields
for each tumor were measured with Image Pro Plus version
6.2 software (Media Cybernetics, Silver Spring, MD).
Statistical analysis. Each experiment was repeated two or
three times. Data are presented as means ± SD. Statview 5.0
software was used for statistical analyses. Statistical
comparisons between control and experimental groups were
performed using the ¯2 test (for incidence only) and the
Student's t-test. Differences were considered to be statistically
significant at P<0.05.
Results
MUC1 is expressed in NSCLC cell lines and is regulated by
STAT3. The protein expression levels of MUC1-C and total
and tyrosine phosphorylated STAT3 were determined in
14 human NSCLC cell lines (Fig. 1A). We observed high
levels of MUC1 protein in 8 cell lines. Consistent with our
hypothesis that STAT3 regulates MUC1, cells with high
levels of MUC1 generally had enhanced levels of phosphorylated STAT3 (3,4). Conversely, in H1299 and PC-9
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Figure 1. MUC1 is widely overexpressed in NSCLC cells, correlating with STAT3 activation. (A) Protein expression of MUC1-C and total and Tyr705
phosphorylated STAT3 levels were determined in 14 human NSCLC cell lines by Western blot analyses. Equal loading and transfer were shown by repeat
probing with ß-actin. (B) mRNA levels of MUC1 in a subset of cells were evaluated with real-time RT-PCR. MUC1 mRNA expression levels in each cell line
were normalized to GAPDH mRNA, with expression in A549 cells set to an arbitrary value of 1. *P<0.01 compared with A549 or H460 cells. (C) Cells were
treated with 700 nM antisense STAT3 oligonucleotides for ~24-48 h, and the effects on MUC1 expression and PARP cleavage were analyzed by Western blot
analysis. Equal loading and transfer were shown by repeat probing with ß-actin. (D) A549 cells were infected with either control adenovirus (Ad-GFP) or AdSTAT3C for 13 h along with low levels of IL-6 for an additional 5 h to enhance STAT3C tyrosine phosphorylation. mRNA levels of MUC1 expression were
determined by real-time RT-PCR assay and normalized to GAPDH mRNA, with expression in Ad-GFP cells set to an arbitrary value of 1. *P<0.01, **P<0.05
compared with Ad-GFP cells.

cells, MUC1 was minimally expressed and this corresponded
to low levels of phosphorylated STAT3. To determine whether
the enhanced levels of protein represent enhanced levels of
MUC1 gene transcription, we examined the mRNA levels of
MUC1 in a subset of the cells evaluated by real-time
quantitative PCR assay. As shown in Fig. 1B, MUC1 mRNA
expression levels in both H1975 and H1650 cells with
enhanced STAT3 activation were markedly higher than in
A549 and H460 cells with lower STAT3 activation. These
results demonstrate that enhanced MUC1 gene expression
contributes to enhanced levels of MUC1 protein in lung
cancer cell lines and suggest that activated STAT3 could be
responsible for the expression of MUC1.
To investigate the possibility that activated STAT3
mediates MUC1 expression, STAT3 was knocked down
using antisense STAT3 oligonucleotides, and the effect on
MUC1 expression was evaluated. As shown in Fig. 1C,
STAT3 protein levels of 3 cell lines were reduced by
antisense STAT3 oligonucleotide treatment resulting in
downregulated levels of MUC1 proteins and cellular apoptosis
(increased PARP cleavage). The lack of complete inhibition
of MUC1 by antisense STAT3 could be secondary to
incomplete STAT3 inhibition or may suggest that other

pathways also contribute to MUC1 expression in these lung
cancer cells. To provide further evidence linking STAT3 to
MUC1, we overexpressed a STAT3 mutant (STAT3C) which
constitutively binds DNA and has enhanced transcription
with costimulatory tyrosine phosphorylation in lung cancer
cells and examined the effects on MUC1 gene expression
(29,30). Cells that received STAT3C had increased mRNA
levels of MUC1 expression compared to cells that received
no STAT3C (Fig. 1D). Therefore, as shown by two different
methods, STAT3 regulates MUC1 expression at both the
mRNA and protein levels in lung cancer cells.
MUC1 functions to drive cell survival and colony formation
in vitro. We next exposed NSCLC cell lines to MUC1 siRNA
followed by assessment of cellular viabilty. In Fig. 2A, in 12
of 14 cell lines, cellular viability was inhibited by MUC1
siRNA treatment compared to results in the control samples.
In these 12 cell lines, MUC1 knockdown by siRNA resulted
in modest (~1.6- to 3.1-fold of the control) increases in cellular
apoptosis (Fig. 2B). These results indicate that apoptosis
contributes to the inhibitory effects of MUC1 siRNA treatment
of NSCLC cells. Given the modest effects, we examined the
effects of MUC1 knockdown using colony formation assay.
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Figure 2. MUC1 functions to drive cell survival and colony formation.
(A) Cells were exposed to siRNA for 120 h, and proliferation rates were
measured by MTT assay. *P<0.01, **P<0.05 compared with the control.
(B) Cells were exposed to siRNA for 72 h, and cell apoptosis evidenced by
positive cells of active caspase-3 in the cells was assessed by flow cytometry
analysis. Relative units of apoptosis for the control were set to 1; data for the
MUC1 siRNA are shown as fold change relative to control siRNA. (C) Cells
treated with siRNA were grown in RPMI-1640 medium supplied with 10%
FBS, and colonies were counted after 14 days. *P<0.01, **P<0.05 compared
with the control.

MUC1 knockdown cells displayed ~25-63% reduction in
colony formation compared to control samples (Fig. 2C).
These results suggest that MUC1 may play an important role
in the survival of NSCLC cells.
MUC1 knockdown modulates STAT3, Src, FAK, and Akt
signaling pathways in NSCLC cells. To investigate the
signaling proteins that are affected by MUC1, we examined
the effect of MUC1 knockdown or overexpression on
activated STAT3, Akt, Src, and FAK in NSCLC cells. These
proteins were chosen for analysis based on earlier studies
suggesting they interact with MUC1 or mediate effects of
MUC1 signaling (8,10). H358, HCC827, and H441 cells
were exposed to MUC1 siRNA for 72 h, and the effects on
phosphorylated signals were detected by Western blot
analysis. Exposure of these cell lines to MUC1 siRNA was
associated with downregulation of MUC1 protein (Fig. 3A).
As shown in Fig. 3A, transfection of cells with MUC1 siRNA
resulted in downregulation of phosphorylated tyrosine
STAT3, Src, and FAK. The phosphorylated serine Akt,
however, was downregulated by MUC1 siRNA only in H358
cells but not in HCC827 and H441 cells, indicating that
MUC1 affects various signals in a cell type-dependent
manner; whereas, the total proteins of STAT3, Src, FAK, and
Akt were not changed by MUC1 siRNA compared to the
control (data not shown). The results in HCC827 are consistent
with prior studies indicating that mutant EGFR/HER3
signaling is the major regulator of PI3K/Akt in these cells
(31). Conversely, in A549 cells transfected with MUC1-C

plasmid, levels of the phosphorylated tyrosine proteins
STAT3, Src, FAK, and serine phosphorylated Akt were
increased (Fig. 3B). These results suggest that in some cell
contexts MUC1 regulates activation of STAT3, Src, FAK, and
Akt signals in NSCLC cells. We also examined the effect of
MUC1 knockdown on anti-apoptotic proteins. Reduction of
anti-apoptotic Bcl-XL, but not Bcl-2, was observed with
suppressed MUC1 levels along with cleaved PARP in all 3
cell lines (Fig. 3A). These findings indicate that MUC1
knockdown leads to cellular apoptosis via pathways involving
Bcl-XL, and MUC1 functions as an oncoprotein to modulate
cell survival associated with the Bcl-2 family.
MUC1 knockdown sensitizes NSCLC cells to cisplatin
treatment. The reduced levels of Bcl-XL in response to
MUC1 knockdown suggested that MUC1 knockdown could
further sensitize NSCLC cells to chemotherapy-induced
apoptosis. To investigate the effects of constitutively overexpressed MUC1 on sensitivity of NSCLC cells to conventional chemotherapeutics, MUC1 siRNA-treated cells were
exposed to increasing concentrations of cisplatin, and cell
viability was assessed after 48 h and compared with control
siRNA-treated cells. As shown in Fig. 4A-C, MUC1 siRNA
treatment and exposure to cisplatin resulted in a significantly
decreased number of viable cells and a leftward shift of the
IC50 of cisplatin compared with cells treated with control
siRNA. These results along with previous findings indicate
that MUC1 knockdown sensitizes NSCLC cells to chemotherapeutics (22).
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Figure 3. Effects of MUC1 knockdown or overexpression on multiple cell signals in NSCLC cells. (A) H358, HCC827, and H441 cells were exposed to
siRNA for 72 h, and (B) A549 cells were transfected with MUC1-C plasmid for 48 h followed by measurement of phosphorylated tyrosine STAT3, Akt, Src,
FAK, and apoptotic-related proteins by Western blot analysis. Equal loading and transfer were shown by repeat probing with ß-actin.

Figure 4. MUC1 knockdown sensitizes NSCLC cells to cisplatin treatment and inhibits metastasis potential. H358 (A), HCC827 (B), and H441 (C) cells were
treated with 20 nM siRNA for 72 h, collected and plated in 96-well plates at a density of 10,000 cells/well, and allowed to grow for ~18-24 h before a 48-h
exposure to cisplatin in dose gradient. Percentage of cell viability was qualified by MTT assay. IC50 of cisplatin was calculated using Matlab software.
◆, control siRNA + CDDP; ƒ, MUC1 siRNA + CDDP. (D) MUC1 overexpressing cell lines (H358, HCC827, and H441) were transfected with 20 nM siRNA
for 72 h and then assessed for migration and invasion as described in Materials and methods. *P<0.01, **P<0.05 compared with the control.
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Figure 5. MUC1 knockdown induces apoptosis in vivo and inhibits orthotopic tumor growth in CD-1 nude mice. (A) Lung tissue specimens subjected to H&E
staining and immunohistochemical analysis of MUC1 and Ki-67 expression and apoptosis (Apop). *P<0.01, **P<0.05 compared with the control. (B) Results
of orthotopic tumor growth evaluation using Xenogen 200 imaging system. *P<0.01 compared with the control. (C) Seven mice for each group were sacrificed
6 weeks after tumor injection when control mice became moribund. §, weight designates lung and tumor weight; #, number of positive mice/number of treated
mice; *P<0.05 compared with the control siRNA group.
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MUC1 siRNA treatment inhibits the cellular metastasis
potential in vitro. We subsequently determined the effects of
MUC1 knockdown on the in vitro migration and invasive
ability of NSCLC cells. Our data and those of others suggest
that Src and its substrate FAK, two important mediators of
cell invasion and metastasis, are possible downstream targets
of MUC1 (10). As shown in Fig. 4D, cells exposed to siRNA
against MUC1 demonstrated statistically significant
reductions in both migration and invasion, although MUC1
siRNA treatment resulted in a relative lower inhibitory effect
on invasive properties of H441 cells than in the other two cell
lines. These results indicate that aberrantly overexpressed
MUC1 protein plays a role in the invasion and migration of
NSCLC cells in addition to its role in cell survival.
MUC1 knockdown inhibits orthotopic tumor growth and
metastasis. To further investigate the effect of MUC1 on
tumor growth and metastasis in mice, H358 cells stably
expressing luciferase were exposed to control siRNA or
MUC1 siRNA, and equal amounts of viable cells were injected
directly into mouse lungs to create orthotopic mouse lung
cancer models. These orthotopic models of human lung cancer
have been suggested to be more clinically relevant since the
tumors originate in the correct microenvironment, can produce
pleural and lymph node metastasis which mimics the human
syndrome of lung cancer, and recapitulate drug sensitivity
better than standard subcutaneous tumor models (28,32).
Within 10 days of injection, microscopic lung tumors were
established in both groups and were subjected to immunohistochemical analyses of MUC1, Ki-67 to examine cellular
proliferation, and ApopTag to examine for apoptosis 10 days
after injection. MUC1 expression was reduced in MUC1knockdown lung tumors indicating a relative durable effect
of the siRNA in this tumor model despite the transient
transfection (Fig. 5A). Measurement of the percentage of cells
positive for ApopTag showed that MUC1 knockdown resulted
in a significant increase in apoptosis compared with the control
(Fig. 5A). MUC1 siRNA-transfected cells also expressed less
Ki-67 indicative of reduced proliferation of these cells in vivo.
Orthotopic tumor growth in the MUC1-knockdown group
was significantly delayed compared with the control group,
as detected by bioluminescence assay after six weeks of in vivo
tumor growth (Fig. 5B). Analysis of lung weight was
performed as a surrogate of tumor mass, and in agreement
with the bioluminescence data we found significant decreases
in lung weight in MUC1 siRNA-treated cells compared to the
control. In addition, we found evidence for reduced metastatic
potential as the mice with MUC1 siRNA-treated H358 cells
had a reduced incidence of mediastinal metastasis and pleural
effusions (Fig. 5C). These results support the hypothesis that
MUC1 regulates in vivo growth, survival, and metastasis of
lung cancer cells.

promoter can be stimulated by STAT transcription factors via
a STAT-binding site in its promoter (7). In addition, our
results strongly suggest that STAT3 plays a role in regulating
MUC1 expression at the mRNA and protein levels. Our
results add MUC1 as a downstream target of STAT3 which
can contribute to the STAT3-dependent phenotype in lung
cancer cells (2,4,27,33). These results are consistent with
clinical studies in lung cancer showing that MUC1 marks
tumors for aggressiveness and suggests that STAT3-MUC1
could be a good molecular pathway target to inhibit tumor
growth and metastasis as well as sensitize tumor cells to
cytotoxic chemotherapy.
In our studies we found evidence that MUC1 contributed
to the activation of STAT3, Akt, Src, and FAK in NSCLC
cells although the exact mechanism is unclear. Many of the
oncogenic effects of MUC1 stem from its cytoplasmic tail,
which binds to several proteins implicated in cancer,
including c-Src, EGFR, and downstream signals (10,16,17,19).
MUC1 has been shown to affect c-Src signaling in mouse
mammary tumor virus-driven polyoma middle T-antigen
(PyV MT)-induced mammary tumorigenesis (10). Phosphorylation of MUC1 Tyr46 functions as a binding site for
the c-Src SH2 domain via which EGFR and c-Src regulate
downstream signals such as ß-catenin and GSK3ß (17). A
large scale analysis of tyrosine phosphorylated proteins in
NSCLC did identify peptides corresponding to Tyr46 in cell
lines and tumors (34). Thus, the cytoplasmic tail could be
important in allowing signaling events to be controlled by
MUC1 in lung cancer cells.
It is likely that other signals besides STAT3 cooperate to
regulate MUC1 in lung cancer cells. Previous studies in
thyroid cells demonstrated that both JAK1/STAT6 and
PI3K/Akt pathways differentially affect MUC1 expression at
mRNA and protein levels (35). JAK/STAT signaling is
mainly thought to modulate MUC1 transcription while PI3K/
Akt signaling is thought to affect MUC1 protein half-life.
Overall these results suggest that MUC1, as a downstream
target of STAT3, interacts or co-regulates with multiple
signals to mediate cell survival and metastasis in NSCLC
cells.
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